14 results about "INSULIN PREPARATIONS" patented technology

An insulin formulation and a method of preparing and using same. The insulin preparation includes insulin, oligosaccharide and sodium chloride at a ratio of 1:A:B (w:w:w respectively) with ranges of A and B are 1000-5000 and 10-50, respectively.

A method may comprise (a) inserting an insulin delivery device subcutaneously into a body of a subject, which comprises an amperometric glucose sensor comprising an electrode layer comprising an indicating electrode and underlying a redox-catalytic layer comprising a redox mediator; (b) using said insulin delivery device to deliver an insulin formulation (e.g., comprising a phenol or cresol excipient) subcutaneously to said subject; and (c) using said amperometric glucose sensor to measure a subcutaneous glucose concentration, which comprises using said redox-catalytic layer to allow electron transfer from subcutaneous glucose to said indicating electrode sufficient to cause a response of said amperometric glucose sensor at an applied bias potential of no more than +250 millivolts, wherein (b) and (c) are performed at the same time for at least one hour, while maintaining a sensor sensitivity of at least 50% of an initial sensor sensitivity for up to one hour.

The present invention relates to insulin formulations comprising polysorbate 80. The present invention provides, inter alia, aqueous liquid pharmaceutical formulations comprising insulin or an insulin analogue, ionic zinc, a chelating agent, and polysorbate 80.

Provided are an acylated insulin preparation, a pharmaceutical composition of acylated insulin and a long-acting GLP-1 compound, and the medical use thereof. The preparation and the pharmaceutical composition have satisfactory physical stability, chemical stability, and safety.

Providing modified insulin and glucokinase nucleic acids for treating diabetes SOLUTION: Reducing hyperglycaemia and maintaining euglycaemia are the goals of all therapeutic approaches to the T1DM and T2DM. Current therapy for most diabetics is based on regular subcutaneous injections of both short-acting and long-acting insulin preparations. The present disclosure relates to modified nucleic acid sequences encoding insulin and glucokinase, expression cassettes and delivery vectors comprising the same, and methods for their delivery to treat diabetes.SELECTED DRAWING: None

The invention relates to a preparation method and application of sugar-responsive protamine insulin, which comprises the following steps: modifying a chemical group on cysteine of protamine, connecting with a phenylboronic acid compound to form a compound, and mixing with insulin to prepare the sugar-responsive protamine insulin. The sugar-responsive insulin preparation can realize an intelligent sugar-responsive regulation mechanism. Specifically, the insulin can be slowly released at a normal blood glucose level and is accelerated to be released at a hyperglycemia state, so that the blood glucose is effectively regulated and controlled, and the occurrence of hypoglycemia is avoided.

The invention relates to the technical field of medical instruments, and discloses a portable insulin intelligent constant-temperature protection device and method based on a phase-change material, the portable insulin intelligent constant-temperature protection device based on the phase-change material comprises a shell, a phase-change material layer, a vacuum heat insulation layer and an insulin constant-temperature control circuit; a storage cavity capable of accommodating an insulin preparation is formed in the middle of the shell; a phase change material layer and a vacuum heat insulation layer are sequentially arranged on the outer side of the storage cavity from inside to outside; the phase-change material layer is used for maintaining the temperature of the storage cavity within the optimal storage temperature range of the insulin preparation; the vacuum heat insulation layer is used for preventing external environment heat from being transferred into the storage cavity; the insulin constant-temperature control circuit is arranged on the shell to monitor the temperature in the storage cavity in real time. The temperature in the storage cavity can be kept stable for a long time under the condition that external power supply is not needed, and real-time monitoring and abnormity alarming of the storage temperature are achieved.

This invention relates to a method for preparing glucose-responsive protamine insulin and its application. The method involves modifying chemical groups on the cysteine ​​residues of protamine and linking them with phenylboronic acid compounds to form a complex, which is then mixed with insulin to prepare glucose-responsive protamine insulin. This glucose-responsive insulin formulation achieves an intelligent glucose response regulation mechanism. Specifically, under normal blood glucose levels, the insulin is released slowly, while under hyperglycemic conditions, its release is accelerated, thereby achieving effective blood glucose control and preventing hypoglycemia.

An insulin formulation and a method of preparing and using same. The insulin preparation includes insulin, oligosaccharide and sodium chloride at a ratio of 1:A:B (w:w:w respectively) with ranges of A and B are 1000-5000 and 10-50, respectively.

The invention relates to an aqueous pharmaceutical formulation having insulin, an insulin analog, or an insulin derivative, and methionine; and to the production thereof, to the use thereof for treating diabetes mellitus, and to a medication for treating diabetes mellitus.

It is provided an insulin formulation comprising insulin and antimicrobial excipients for use in insulin pumps, connected to subcutaneous tissue via a catheter, a method also known as continuous subcutaneous insulin infusion, wherein the antimicrobial excipient inhibits growth of bacteria in insulin formulations and biofilm bacterial population formation on the internal surfaces of a catheter, allowing extending the time of use of the catheter.

The invention discloses a solid-phase synthesis insulin glargine preparation process, which belongs to the technical field of biological pharmacy, and comprises the following steps: S1, carrying out solid-phase synthesis on an insulin A chain through Wang resin, removing a protecting group, and then oxidizing by using NCS to form a first pair of disulfide bonds: sequentially inoculating amino acids according to an Fmoc solid-phase synthesis method by using NCS as an oxidizing agent and Wang resin as a solid-phase carrier, so as to obtain a second pair of disulfide bonds; constructing an A chain sequence; s2, performing solid-phase synthesis of insulin B chain by Wang resin, grafting DTDP after cutting, and purifying; s3, butting the A chain solution and the B chain solution to form a second pair of disulfide bonds; and S4, constructing a third pair of disulfide bonds by adopting an iodine oxidation method. According to the method, disulfide bonds can be directionally formed and constructed in three steps, non-specific crosslinking is avoided through selective oxidation of NCS, DTDP and iodine, correct folding of molecules is ensured, the total yield of the three-step disulfide bond forming process reaches 28% and is increased by 13% compared with one-pot oxidation, and the yield is increased; the process is controllable, and the industrial adaptability is high.